vs
Side-by-side financial comparison of Eastern Bankshares, Inc. (EBC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Eastern Bankshares, Inc. is the larger business by last-quarter revenue ($295.9M vs $177.4M, roughly 1.7× Pacira BioSciences, Inc.). Eastern Bankshares, Inc. runs the higher net margin — 22.1% vs 1.6%, a 20.4% gap on every dollar of revenue. On growth, Eastern Bankshares, Inc. posted the faster year-over-year revenue change (710.6% vs 5.0%). Over the past eight quarters, Eastern Bankshares, Inc.'s revenue compounded faster (38.6% CAGR vs -0.2%).
Eastern Bank is a bank based in Boston, Massachusetts. Before de-mutualizing in 2020, it was the oldest and largest mutual bank in the United States and the largest community bank in Massachusetts.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
EBC vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $177.4M |
| Net Profit | $65.3M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 22.1% | 1.6% |
| Revenue YoY | 710.6% | 5.0% |
| Net Profit YoY | -34.4% | — |
| EPS (diluted) | $0.29 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $295.9M | $177.4M | ||
| Q4 25 | $37.5M | $196.9M | ||
| Q3 25 | $241.5M | $179.5M | ||
| Q2 25 | $244.9M | $181.1M | ||
| Q1 25 | $31.1M | $168.9M | ||
| Q4 24 | $216.5M | $187.3M | ||
| Q3 24 | $203.4M | $168.6M | ||
| Q2 24 | $154.0M | $178.0M |
| Q1 26 | $65.3M | $2.9M | ||
| Q4 25 | $99.5M | — | ||
| Q3 25 | $106.1M | $5.4M | ||
| Q2 25 | $100.2M | $-4.8M | ||
| Q1 25 | $-217.7M | $4.8M | ||
| Q4 24 | $60.8M | — | ||
| Q3 24 | $-6.2M | $-143.5M | ||
| Q2 24 | $26.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | 38.9% | 3.5% | ||
| Q2 25 | 41.0% | 4.7% | ||
| Q1 25 | -590.9% | 1.2% | ||
| Q4 24 | 33.3% | 13.2% | ||
| Q3 24 | -1.6% | -82.8% | ||
| Q2 24 | 24.7% | 15.9% |
| Q1 26 | 22.1% | 1.6% | ||
| Q4 25 | 265.6% | — | ||
| Q3 25 | 44.0% | 3.0% | ||
| Q2 25 | 40.9% | -2.7% | ||
| Q1 25 | -699.2% | 2.8% | ||
| Q4 24 | 28.1% | — | ||
| Q3 24 | -3.0% | -85.1% | ||
| Q2 24 | 17.1% | 10.6% |
| Q1 26 | $0.29 | $0.07 | ||
| Q4 25 | $0.48 | $0.05 | ||
| Q3 25 | $0.53 | $0.12 | ||
| Q2 25 | $0.50 | $-0.11 | ||
| Q1 25 | $-1.08 | $0.10 | ||
| Q4 24 | $0.29 | $0.38 | ||
| Q3 24 | $-0.03 | $-3.11 | ||
| Q2 24 | $0.16 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $551.7M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.3B | $653.9M |
| Total Assets | $30.6B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $551.7M | $144.3M | ||
| Q4 25 | $507.6M | $238.4M | ||
| Q3 25 | $703.4M | $246.3M | ||
| Q2 25 | $948.3M | $445.9M | ||
| Q1 25 | $609.0M | $493.6M | ||
| Q4 24 | $1.9B | $484.6M | ||
| Q3 24 | $1.7B | $453.8M | ||
| Q2 24 | $1.4B | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $4.3B | $653.9M | ||
| Q4 25 | $4.3B | $693.1M | ||
| Q3 25 | $3.8B | $727.2M | ||
| Q2 25 | $3.7B | $757.8M | ||
| Q1 25 | $3.6B | $798.5M | ||
| Q4 24 | $3.6B | $778.3M | ||
| Q3 24 | $3.7B | $749.6M | ||
| Q2 24 | $3.0B | $879.3M |
| Q1 26 | $30.6B | $1.2B | ||
| Q4 25 | $30.6B | $1.3B | ||
| Q3 25 | $25.5B | $1.3B | ||
| Q2 25 | $25.5B | $1.5B | ||
| Q1 25 | $25.0B | $1.6B | ||
| Q4 24 | $25.6B | $1.6B | ||
| Q3 24 | $25.5B | $1.5B | ||
| Q2 24 | $21.0B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EBC
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
